Leader Beike Biotech and China’s Tsinghua University receive
USD $4 million for stem cell reprogramming laboratory
on: November 7, 2007, 7:01 pm
Release Author: Jai Communications
Release Summary: Patients suffering from a range of debilitating
illnesses, such as spinal cord injury, cerebral palsy, optic nerve
hypoplasia, multiple sclerosis and ataxia stand to benefit from
a new laboratory, established with a Chinese Government grant. Such
a facility will put China at the forefront of the global race to
engineer and reprogram human stem cells for positive medical benefit.
Release Body: November 7, 2007 - SHENZHEN, China – Beike
the leader in stem cell applications for medical treatment, has
announced that it has formally established a world-class laboratory
facility for the research of cell reprogramming and gene engineering,
through a joint agreement with the Shenzhen Graduate School
of China’s renowned Tsinghua University. The lab
will conduct research on stem cells, the nuclear transfer and reprogramming
of cells, monoclonal antibodies known as “magic bullets”
for treating disease and other scientifically exciting cell engineering
innovations. The aim of the lab is to establish a global research
hub that will hopefully someday provide breakthroughs in the way
medical science seeks to treat diseases like cancer, Parkinson’s,
and many other debilitating ailments.
are already helping thousands of patients with our current umbilical
cord stem cell treatments, but this ultra high-tech lab will bring
us even closer to our goal of helping millions of patients improve
their quality of life and will ensure that we have more advanced
products in our pipeline four to five years out.” said
Beike Biotech’s Chairman, Dr. Sean Hu. Detailed
patient experiences with videos of patients that have been treated
with Beike’s umbilical cord treatment can
be found on China’s stem cell news website: http://www.stemcellschina.com.
1,200 square meter laboratory will be housed in Beijing-based Tsinghua
University’s special Shenzhen Graduate Campus located in this
southern Chinese city that borders Hong Kong. Building on Beike’s
years of experience in successfully using stem cells to treat humans
with serious brain and nerve maladies, this designated “China
Key Laboratory” marks the country’s entry into
the current global race to find new stem cell therapies that can
be applied medically. The USD $4 million grant will be spent purely
on equipment and comes from the Shenzhen Municipal Government as
part of a US$12 million grant given out in 2007 to encourage innovative
technologies in Shenzhen.
grants from the government are expected to help cover the cost of
running the lab and expansion. The lab is to be staffed by over
50 people, including 20 renowned Chinese Phd’s and well-known
researchers like Dr. Zhang Hai, who has published
articles widely in Western periodicals, for example, “Nature”
of her breakthroughs in research of microRNA and other cell building
Zhang Hai is a pioneer and our work with her will allow
Beike to lead the world not only in clinical applications
of stem cells but also in basic research. Outside of China, it is
not easy to get a 20 Phd’s together in a first class lab focusing
on stem cell research. We expect to have some breakthroughs come
out of this and more publications in leading journals,” Dr.
Sean Hu said.
cells are the master cells that replenish all the body's
tissues, from skin and blood to the brain and heart. They have proven
capability to assist in nerve and organ regeneration, enable tissue
repair and restoration, and are even thought to be able to effectively
treat cardiovascular diseases and cancer. Beike
currently has seen significant success using stem cells to treat
a variety of nervous system disorders for Chinese and International
patients alike. (Details can be found at http://www.stemcellschina.com).
Many of these conditions are still deemed untreatable using conventional
medical techniques and account for an estimated 60% of gross mortality
worldwide. While not currently possible, scientists in labs like
the one being established in Shenzhen are narrowing in on the technology
that may soon allow for the reprogramming of human body cells. This
would allow for the potential to regenerate nerve cells to heal
spinal cord injuries, create one’s own pancreatic cells to
stop diabetes, or possibly generate cells of any other tissue type
to treat whatever ails patients. This makes the successful application
of stem cells of vital significance to human health and the medical
Beike Biotechnology Company Limited
is a biotechnology company that was founded in July 2005 with capital
from Beijing University, Hong Kong University of Science and Technology
and Shenzhen City Hall when it commercialized stem cell technology
that had been in research since 1999. As a private high-tech enterprise,
it is dedicated to the clinical application of stem cell research.
It is also supported with funds from the China State National Fund.
The research and clinical work is a collaboration of Beijing University,
Hong Kong University of Science and Technology, No. 3 Army Medical
University, Zhongshan Medical University, Guiyang Medical College
and Zhengzhou University.
The Graduate School at Shenzhen, Tsinghua University
The Graduate School of Tsinghua University in Shenzhen
is an institute jointly established by Shenzhen City Hall and Tsinghua
University to provide training for talent at the postgraduate level
in science and technical innovation. As the only non-Beijing located
educational facility run by Tsinghua University, the Graduate School
of Tshinghua in Shenzhen is committed to the integration of teaching,
research, and rapid commercialization of scientific discovery.
more information, please contact:
Beike Biotech Company, Ltd.
Shenzhen Hi-Tech Industrial Park
Details: Jai Communications
MBE#056, 3rd Fl, Silom Complex, 191 Silom Road, Bangrak, Bangkok,
to previous page...
to home page...
your press releases...